Avantium Technologies have announced that they have a collaboration with GlaxoSmithKline for the extensive screening of several GSK pharmaceutical compounds utilizing Avantium’s high-throughput polymorph, salt and co-crystal screening capabilities to find novel solid forms.
Avantium Technologies is an innovation-based company and its unique integrated screening platform provides a fast and efficient way to explore a wide array of crystallization conditions to generate and identify novel solid forms.
“We welcome this great opportunity to collaborate with GlaxoSmithKline,” said Guus Scheefhals, Chief Business Officer of Avantium Technologies. “It is an honor to contribute to the development of GSK’s therapeutic products by using our highthroughput technology platform and rational experimental design strategy. This intensive partnership is a valuable recognition of our capabilities.“